Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
2.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
3.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
4.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
5.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med
; 377(4): 338-351, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578639
6.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464
7.
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
BJU Int
; 121(2): 268-274, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28940952
8.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet
; 387(10024): 1163-77, 2016 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26719232
9.
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
BJU Int
; 119(4): 522-529, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27256016
10.
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Lancet Oncol
; 15(4): 464-73, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24581940
11.
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
Lancet Oncol
; 13(5): 549-58, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22452894
12.
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PLoS One
; 17(6): e0269192, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653395
13.
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
J Clin Oncol
; 40(8): 825-836, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34757812
14.
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
JNCI Cancer Spectr
; 6(4)2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877084
15.
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial.
BJU Int
; 111(5): 697-9, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23578233
16.
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Eur Urol Oncol
; 1(6): 449-458, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31158087
17.
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
J Clin Oncol
; 35(14): 1530-1541, 2017 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28300506
18.
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
JAMA Oncol
; 2(3): 348-57, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26606329
19.
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
Eur Urol
; 67(6): 1028-1038, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25301760
20.
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Eur Urol
; 66(5): 799-802, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24985962